Daiichi Sankyo Co., Ltd.
115
4
18
87
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 15/100
8.7%
10 terminated/withdrawn out of 115 trials
89.7%
+3.2% vs industry average
32%
37 trials in Phase 3/4
67%
58 of 87 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (115)
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Role: collaborator
DS-3201b in Participants With Lymphomas
Role: lead
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.
Role: collaborator
A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors
Role: collaborator
Phase 2 Study of Trastuzumab Deruxtecan in the Neoadjuvant Treatment, or Trastuzumab Deruxtecan Plus Capecitabine Plus Durvalumab(MEDI4736) in the Preoperative and Postoperative Adjuvant Treatment for Patients With HER2 Positive Gastric and Gastroesophageal Junction Adenocarcinoma
Role: collaborator
A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations
Role: collaborator
A Study of DS-1001b in Patients With Chemotherapy- and Radiotherapy-Naive IDH1 Mutated WHO Grade II Glioma
Role: lead
A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan
Role: lead
DS-8201a in Pre-treated HER2 Breast Cancer That Cannot be Surgically Removed or Has Spread [DESTINY-Breast02]
Role: collaborator
HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer
Role: collaborator
A Study of PLX3397 in Patients With Unresectable or Metastatic KIT-mutated Melanoma
Role: lead
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer
Role: collaborator
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
Role: collaborator
A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors
Role: collaborator
First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)
Role: lead
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]
Role: collaborator
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
Role: collaborator
Long-term, Extension Study of DS-5141b in Patients With Duchenne Muscular Dystrophy
Role: lead
A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT
Role: lead
A Study of DS-1471a In Subjects With Advanced Solid Tumors
Role: lead